Zydus Pharmaceuticals USA Inc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Zydus Pharmaceuticals USA Inc Pharmaceutical Import Records from India — 5 Products, $1.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Zydus Pharmaceuticals USA Inc — Pharmaceutical Importer Profile (2026) | 5 Products, $1.6M Trade | TransData Nexus

Zydus Pharmaceuticals USA Inc

Pharmaceutical Importer · United States · Antibiotics Focus · $1.6M Total Trade · DGFT Verified

Zydus Pharmaceuticals USA Inc is a pharmaceutical importer based in United States with a total trade value of $1.6M across 5 products in 4 therapeutic categories. Based on 32 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Zydus Pharmaceuticals USA Inc sources from 2 verified Indian suppliers, with Cadila Healthcare Limited accounting for 100.0% of imports.

Zydus Pharmaceuticals USA Inc — Import Portfolio & Supplier Network

Zydus Pharmaceuticals USA Inc import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Zydus Pharmaceuticals USA Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cadila Healthcare Limited	$7.3M	167	100.0%
Zydus Lifesciences Limited	$168	6	0.0%

Zydus Pharmaceuticals USA Inc sources from 2 verified Indian suppliers across .

What Formulations Does Zydus Pharmaceuticals USA Inc Import?

Formulation	Value	Ships
Metoprolol succinate er TAB 50 MG	$577.7K	12
Atorvastatin calcium tablets USP 40 MG	$469.2K	11
Trazodone hcl tablets USP 150 MG	$387.6K	8
Methotrexate tablets USP 2.5 MG 100's	$250.0K	5
Exemestane tablets 25 MG - 1 x 30.	$250.0K	5
Amitriptyline hcl TAB USP 10 MG	$242.9K	6
Colestipol hydrochloride tablets USP	$200.0K	4
Trazodone hcl tablets USP 100 MG	$192.4K	4
Famotidine tablets USP 40 MG - 1 x 1000.	$189.4K	4
Tiadylt er diltiazem hcl er CAPS	$186.6K	4
Atorvastatin calcium tablets USP 80 MG	$181.7K	4
Esomeprazole magnesium delayed	$176.8K	4
Metoprolol succinate er TAB 25 MG	$150.0K	3
Doxycycline capsules USP 100 MG 50's	$150.0K	3
Triamterene & hydrochlorothiazide TAB	$122.2K	3

Zydus Pharmaceuticals USA Inc imports 93 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Doxycycline	Antibiotics	$650.0K	13	0.5%	14
2	Diltiazem	Cardiovascular	$250.0K	5	1.4%	14
3	Exemestane	Advanced Oncology	$250.0K	5	1.7%	8
4	Methotrexate	Immunosuppressants	$250.0K	5	0.7%	8
5	Atenolol	Cardiovascular	$200.0K	4	0.5%	18

Zydus Pharmaceuticals USA Inc imports 5 pharmaceutical products across 4 categories into United States totaling $1.6M.

Zydus Pharmaceuticals USA Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Zydus Pharmaceuticals (USA) Inc., headquartered in Pennington, New Jersey, is the U.S. division of Zydus Lifesciences Limited, a global healthcare provider based in Ahmedabad, India. Since its first commercial launch in August 2005, Zydus Pharmaceuticals has been dedicated to delivering quality, affordable generic drugs to the U.S. market. The company offers a diverse portfolio of over 500 stock-keeping units (SKUs) and is recognized as one of the top 10 pharmaceutical companies in the U.S. based on unbranded dispensed prescriptions.

Zydus Pharmaceuticals operates as a pharmaceutical importer and distributor, sourcing finished pharmaceutical formulations from India. Its parent company, Zydus Lifesciences Limited, is India's fourth-largest pharmaceutical company, with a global presence in over 50 countries, including the U.S., France, Spain, Brazil, Mexico, and South Africa. The parent company has a legacy of over 70 years and is driven by care, compassion, and a commitment to innovation.

2Distribution Network

Zydus Pharmaceuticals' distribution network is centered in Pennington, New Jersey, serving as the primary hub for its U.S. operations. The company has established partnerships with various logistics providers to ensure efficient distribution across the United States. While specific warehouse locations and logistics capabilities are not publicly detailed, Zydus Pharmaceuticals' extensive product portfolio and market presence suggest a well-developed distribution infrastructure capable of meeting the demands of the U.S. pharmaceutical market.

3Industry Role

In the U.S. pharmaceutical supply chain, Zydus Pharmaceuticals (USA) Inc. functions primarily as a pharmaceutical importer and distributor. The company sources finished pharmaceutical formulations from its parent company, Zydus Lifesciences Limited, and other suppliers, and distributes these products to various stakeholders, including wholesalers, retailers, and healthcare providers. By focusing on the importation and distribution of generic drugs, Zydus Pharmaceuticals plays a significant role in enhancing the accessibility and affordability of medications in the U.S. market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Zydus Pharmaceuticals USA Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Zydus Pharmaceuticals' sourcing strategy exhibits a high degree of concentration, with a significant majority of its imports originating from its parent company, Zydus Lifesciences Limited. This centralized sourcing approach can offer advantages such as streamlined supply chain management and consistent product quality. However, the limited number of suppliers may pose risks related to supply chain disruptions or dependency on a single source. The company's import data indicates a stable relationship with Zydus Lifesciences Limited, as evidenced by the substantial volume of shipments and the absence of significant fluctuations in import values. This stability suggests a well-established and reliable partnership, mitigating potential risks associated with supplier concentration.

2Supply Chain Resilience

Zydus Pharmaceuticals' supply chain resilience is closely tied to its relationship with Zydus Lifesciences Limited, which operates multiple FDA-approved manufacturing facilities in India. The company's sourcing strategy focuses on finished pharmaceutical formulations, encompassing a wide range of dosage forms, including tablets, capsules, creams, ointments, and injectables. This diverse product range enhances supply chain flexibility and reduces dependency on a single product line. While specific details about backup suppliers and shipping routes are not publicly disclosed, the established infrastructure and regulatory compliance of Zydus Lifesciences Limited's manufacturing facilities contribute to the overall resilience of Zydus Pharmaceuticals' supply chain.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth requirements for drug safety, efficacy, and quality. Pharmaceutical imports must comply with FDA regulations, including registration of foreign drug establishments, listing of drug products, and adherence to labeling requirements. The FDA also conducts inspections to ensure compliance with current Good Manufacturing Practice (GMP) standards.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the U.S. include the registration of foreign drug establishments with the FDA and the listing of all drug products intended for import. Manufacturers must comply with FDA's GMP standards, which are aligned with international guidelines such as EU GMP, WHO GMP, and PIC/S. These standards ensure that drug products are consistently produced and controlled to quality standards appropriate for their intended use. Additionally, wholesale distributors must obtain authorization from the FDA to operate legally within the U.S. market.

Quality & Labeling

Zydus Pharmaceuticals USA Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Zydus Pharmaceuticals' product strategy focuses on expanding its portfolio of complex generics, including modified release oral solids, transdermals, injectables, and oral suspensions. This strategic emphasis aligns with market demand for diverse and advanced therapeutic options. The company's import data indicates a concentration in therapeutic categories such as antibiotics, cardiovascular, and advanced oncology, reflecting a targeted approach to address prevalent health conditions in the U.S. By focusing on these areas, Zydus Pharmaceuticals aims to meet the evolving needs of the healthcare market and enhance patient outcomes.

2Sourcing Profile

Zydus Pharmaceuticals' sourcing strategy is centered on importing finished pharmaceutical formulations from its parent company, Zydus Lifesciences Limited, and other suppliers. This approach allows the company to leverage the manufacturing capabilities and product diversity of its parent while ensuring compliance with FDA regulations. The focus on finished formulations enables Zydus Pharmaceuticals to offer a wide range of dosage forms, including tablets, capsules, creams, ointments, and injectables, catering to various patient needs.

3Market Positioning

Seller's Guide — How to Become a Supplier to Zydus Pharmaceuticals USA Inc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Zydus Pharmaceuticals, particularly if they can offer complementary products that align with the company's focus on complex generics and diverse therapeutic areas. Identifying gaps in Zydus Pharmaceuticals' current sourcing, such as unmet needs in specific dosage forms or therapeutic categories, could present avenues for partnership. However, potential suppliers must demonstrate adherence to FDA regulations, including GMP compliance and quality standards, to establish a successful relationship.

2Requirements & Qualifications

Indian exporters seeking to supply Zydus Pharmaceuticals and the U.S. market must obtain FDA approval for their drug products, which involves submitting an Abbreviated New Drug Application (ANDA) or New Drug Application (NDA). Manufacturers must comply with FDA's GMP standards, which are aligned with international guidelines such as EU GMP, WHO GMP, and PIC/S. Additionally, drug products must meet FDA labeling requirements, including the use of the English language and the inclusion of all necessary information. Establishing a partnership with Zydus Pharmaceuticals also requires a commitment to quality, regulatory compliance, and the ability to meet market demands.

Frequently Asked Questions — Zydus Pharmaceuticals USA Inc

What products does Zydus Pharmaceuticals USA Inc import from India?

Zydus Pharmaceuticals USA Inc imports 5 pharmaceutical products across 4 categories. Top imports: Doxycycline ($650.0K), Diltiazem ($250.0K), Exemestane ($250.0K), Methotrexate ($250.0K), Atenolol ($200.0K).

Who supplies pharmaceuticals to Zydus Pharmaceuticals USA Inc from India?

Zydus Pharmaceuticals USA Inc sources from 2 verified Indian suppliers. The primary supplier is Cadila Healthcare Limited (100.0% of imports, $7.3M).

What is Zydus Pharmaceuticals USA Inc's total pharmaceutical import value?

Zydus Pharmaceuticals USA Inc's total pharmaceutical import value from India is $1.6M, based on 32 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Zydus Pharmaceuticals USA Inc focus on?

Zydus Pharmaceuticals USA Inc imports across 4 categories. The largest: Antibiotics (40.6%), Cardiovascular (28.1%), Advanced Oncology (15.6%).

Get Full Zydus Pharmaceuticals USA Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.